RU98121402A - NEW PEPTIDES THAT MAY BE USED IN ANTIGEN-SPECIFIC IMMUNOSUPRESSIVE THERAPY - Google Patents

Claims (9)

1. Peptides consisting of 16-55 amino acid residues, wherein said peptide comprises at least one of the amino acid sequences LVCYYTSWS (SEQ ID NO: 60), FLCTHIIYS (SEQ ID NO: 61), IIYSFANIS (SEQ ID NO: 62), LKTLLSVGG (SEQ ID NO: 63), FIKSVPPFL (SEQ ID NO: 64), FDGLDLAWL (SEQ ID NO: 65), LYPGRRDKQ (SEQ ID NO: 66), YDIAKISQH (SEQ ID NO: 67), LDFISIMTY ( SEQ ID NO: 68), FISIMTYDF (SEQ ID NO: 69), FRGQEDASP (SEQ ID NO: 70), YAVGYMLRL (SEQ ID NO: 71), MLRLGAPAS (SEQ ID NO: 72), LAYYEICDF (SEQ ID NO: 73 ), LRGATVHRT (SEQ ID NO: 74), YLKDRQLAG (SEQ ID NO: 75), LAGAMVWAL (SEQ ID NO: 76), VWALDLDDF (SEQ ID NO: 77) or LDLDDFQGS (SEQ ID N0: 78).  2. A peptide consisting of 16-55 amino acid residues, wherein said peptide includes at least one of the amino acid sequences YKLVCYYTSWSQYREG (SEQ ID NO: 1), YTSWSQYREGDGSCFP (SEQ ID NO: 2), LDRFLCTHIIYSFANI (SEQ ID NO: 5), THIIYSFANISNDHID (SEQ ID NO: 6), PNLKTLLSVGGWNFGS (SEQ ID NO: 12), NTQSRRTFIKSVPPFL (SEQ ID NO: 16), TFIKSVPPFLRTHGFD (SEQ ID NO: 17), PPFLRTHLFGFGFGFGDLFGLDGFGLFGLGFGFD SEQ ID NO: 19), DLAWLYPGRRDKQHFT (SEQ ID NO: 20), TIDSSYDIAKISQHLD (SEQ ID NO: 28), DIAKISQHLDFISIMT (SEQ ID NO: 29), QHLDFISIMTYDFHGA (SEQ ID NO: 30), SPLFRGG ), DYAVGYMLRLGAPASK (SEQ ID NO: 37), MLRLGAPASKLVMGIP (SEQ ID NO: 38), PASKLVMGIPTFGRSF (SEQ ID NO: 39), GTLAYYEICDFLRGAT (SEQ ID NO: 46), EICDFLRGATVHRTLG (SEQ ID NO: 47), RGATVHRTLGQQVPYA (SEQ ID NO: 48), VKSKVQYLKDRQLAGA (SEQ ID NO: 53), YLKDRQLAGAMVWALD ( SEQ ID N0: 54), LAGAMVWALDLDDFQG (SEQ ID NO: 55), WALDLDDFQGSFCGQD (SEQ ID NO: 56) or DFQGSFCGQDLRFPLT (SEQ ID NO: 57).  3. The peptide according to claim 1 or 2, wherein said peptide comprises at least one of the amino acid sequences YKLVCYYTSWSQYREG (SEQ ID NO: 1), YTSWSQYREGDGSCFP (SEQ ID NO: 2), LDRFLCTHIIYSFANI (SEQ ID NO: 5) , THIIYSFANISNDHID (SEQ ID NO: 6), PNLKTLLSVGGWNFGS (SEQ ID NO: 12), QHLDFISIMTYDFHGA (SEQ ID NO: 30), SPLFRGQEDASPDRFS (SEQ ID NO: 34), DYAVGYMLRLGAPASGKLKAPLKAPK (37) NO: 38), YLKDRQLAGAMVWALD (SEQ ID NO: 54) or LAGAMVWALDLDDFQG (SEQ ID NO: 55).  4. The peptide according to any one of paragraphs. 1-3, wherein said peptide includes at least one of the amino acid sequences YTSWSQYREGDGSCFP (SEQ ID NO: 2), SPLFRGQEDASPDRFS (SEQ ID NO: 34), MLRLGAPASKLVMGIP (SEQ ID NO: 38), YLKDRQLAGAMVWALD (SEQ ID NO : 54) or LAGAMVWALDLDDFQG (SEQ ID NO: 55).  5. Hexadecapeptide according to claims. 1-4, wherein said hexadecapeptide consists of at least one amino acid sequence of YKLVCYYTSWSQYREG (SEQ ID NO: 1), YTSWSQYREGDGSCFP (SEQ ID NO: 2), LDRFLCTHIIYSFANI (SEQ ID NO: 5), THIIYSFANISNDHID : 6), PNLKTLLSVGGWNFGS (SEQ ID NO: 12), QHLDFISIMTYDFHGA (SEQ ID NO: 30), SPLFRGQEDASPDRFS (SEQ ID NO: 34), DYAVGYMLRLGAPASK (SEQ ID NO: 37), MLRLGAPASKLVMKLVMKLVMKLVMKLVMKLVMKLVMKLVMKLVM (SEQ ID NO: 54) or LAGAMVWALDLDDFQG (SEQ ID NO: 55).  6. The peptide according to any one of paragraphs. 1-5, which can be used as a medicinal substance.  7. A pharmaceutical composition comprising one or more peptides according to any one of paragraphs. 1-5, as well as a pharmaceutically acceptable carrier.  8. A diagnostic method for detecting activated autoreactive T cells, comprising the following steps: a) separating peripheral mononuclear blood cells (PBMC) from an individual blood sample, b) culturing said peripheral mononuclear blood cells under suitable conditions, c) incubating said culture of peripheral mononuclear cells in the presence of one or more peptides according to any one of paragraphs. 1-5, d) determining a T cell response, for example, a proliferative reaction, meaning the presence of activated autoreactive T cells in an individual.  9. A test kit for determining activated autoreactive T cells, wherein said test / kit includes one or more peptides according to any one of claims. 1-5.